Dr. Agarwals Health Care Ltd (AGARWALEYE) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company demonstrated steady momentum in Q2 FY26, building on the trends from the first quarter and achieving a total income of INR 507 crores for the quarter.
- Profitability saw significant improvement, with quarterly PAT growing 71% year-on-year to INR 36 crores, driven by cost efficiencies and lower finance costs.
- Network expansion continued robustly, with the commissioning of 11 new facilities in Q2, bringing the total network to over 258 facilities and strengthening the company's presence across India.
- The company maintained a strong focus on clinical excellence and technology adoption, reflected by a 69% YoY growth in high-end robotic cataract surgeries (Femto Cataract) in H1 FY26.
- The Southern region remained the primary revenue driver, contributing 64% of total group revenues, while the company is actively expanding its footprint in the North, West, and East regions to build scale.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.